Second generation IL-2 therapy set to boost checkpoint inhibitors
Companies are now working to bring modified versions of IL-2 to market to treat cancer, combining this cytokine with checkpoint inhibitors. These companies are well funded, and the diversity of approach, with at least three distinct strategies, offers hope that more than one improved IL-2 drug may eventually be approved.